To read the full story, subscribe or sign in.

BMS’ Opdivo greenlighted as first immunotherapy for first-line advanced gastric cancer in China

Sep. 7, 2021

Bristol Myers Squibb Co.’s Opdivo (nivolumab) is now the first and only immunotherapy for the first-line treatment of advanced gastric cancer in China.

BioWorld Asia Regulatory Cancer China NMPA

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 1, 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Japan approves first self-amplifying mRNA COVID-19 vaccine from CSL, Arcturus

BioWorld

In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA)...

Avidity, BMS sign $2.3B cardiovascular deal for new RNA class

BioWorld

In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global rights to Avidity’s antibody...

Upgrade your daily dose of biopharma and medtech news

BMS’ Opdivo greenlighted as first immunotherapy for first-line advanced gastric cancer in China